RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed price. Currency in USD
30.415
-0.595 (-1.919%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous close31.010
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's range0.000 - 0.000
52-week range
Volume0
Avg. volume1,205,661
Market cap206B
Beta0.53
PE ratio (TTM)20.79
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & Yield1.03 (3.27%)
Ex-dividend date2017-03-15
1y target estN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal23 hours ago

    [$$] Roche Sales Boosted by New Drugs

    Roche said that third-quarter sales increased 4.9%, boosted by its pipeline of recently launched drugs.

  • Roche's Top Drug Stumbles in Europe as Biosimilars Take Hold
    Bloombergyesterday

    Roche's Top Drug Stumbles in Europe as Biosimilars Take Hold

    Roche Holding AG’s top-selling drug Rituxan saw sales slide in Europe last quarter, hurt by competition from cheaper copycat medicines called biosimilars -- a harbinger of things to come for the aging ...

  • Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
    Zacks2 days ago

    Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

    At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

  • ImmunoGen to Push Leukemia Candidate into Phase I Trial
    Zacks2 days ago

    ImmunoGen to Push Leukemia Candidate into Phase I Trial

    ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.

  • Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
    Zacks3 days ago

    Inovio Initiates Bladder Cancer Study With Roche's Tecentriq

    Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks4 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Forbes7 days ago

    Roche's Blockbuster Oncology Drugs Losing Steam As They Approach Patent Expiry

    Roche Holdings’ oncology business accounts for over 50% of the company valuation, according to our estimates. The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan. These three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016

  • Reuters8 days ago

    'Double whammy' for Roche as manufacturing patent losses loom

    Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. Roche's so-called "Cabilly patents" protect a pivotal step in manufacturing therapeutic antibodies, but end on Dec. 18, 2018. For decades, these patents allowed Roche to extract cash from dozens of drugmakers.

  • Is This the Best Precision Medicine Stock to Buy?
    Motley Fool9 days ago

    Is This the Best Precision Medicine Stock to Buy?

    Foundation Medicine is on the cusp of a tidal shift in cancer treatment.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks11 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
    Zacks11 days ago

    Roche (RHHBY) Receives FDA Approval For Cobas Zika Test

    The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.

  • Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
    Zacks17 days ago

    Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA

    Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.

  • FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
    Zacks17 days ago

    FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

    Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

  • Prothena's Psoriasis Candidate Disappoints in Phase I Study
    Zacks17 days ago

    Prothena's Psoriasis Candidate Disappoints in Phase I Study

    Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.

  • Reuters - UK Focuslast month

    Roche eye drug fails late-stage trial in blow to pipeline

    A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday it now had no future. Lampalizumab, which was being trialled to treat a form of age-related macular degeneration, did not reduce changes in lesion area compared to a placebo after a year, Roche said.

  • Reuters - UK Focuslast month

    Merck's immunotherapy, chemo mix shows extended lung cancer gains

    Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. U.S. regulators approved the drug cocktail in May but the limited clinical trial data to date means that questions still remain as to whether it will retain its effectiveness over time.

  • Roche, the biggest maker of cancer drugs, raises outlook after first-half profit beat
    CNBC3 months ago

    Roche, the biggest maker of cancer drugs, raises outlook after first-half profit beat

    Roche raised its 2007 outlook after first-half profit beat market expectations just as the Swiss group's ageing portfolio of blockbuster medicines faces increasing competition.

  • Reuters - UK Focus3 months ago

    Poor test results for Roche cloud growth prospects

    A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.

  • Reuters - UK Focus3 months ago

    Shire, Roche slug it out in billion-dollar haemophilia drug battle

    Swiss drugmaker Roche's bid to take a chunk of the $11 billion haemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction over its Swiss rival's medication. Shire said its injunction in a court in Germany, where Roche presented data on its drug emicizumab on Monday, sought to remedy Roche's "incomplete and misleading" statements about the role of Shire's drug FEIBA in adverse events in Roche trials.

  • Reuters - UK Focus3 months ago

    Roche, Shire court fight underscores high stakes in haemophilia

    Roche's bid to muscle in on Shire's share of the $11 billion haemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine. Shire's injunction on Sunday in a Hamburg, Germany, court alleges incomplete and misleading statements by Roche about its investigational emicizumab.

  • Reuters - UK Focus4 months ago

    New Roche haemophilia drug prevents bleeds but questions remain

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine. Haemophilia patients' blood does not clot properly, requiring life-saving infusions of clotting factors.

  • Reuters - UK Focus4 months ago

    Roche says new haemophilia drug cuts bleed rate by 87 pct

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday. In the late-stage study, 62.9 percent of patients receiving emicizumab experienced zero treated bleeds compared to 5.6 percent of those receiving so-called bypassing agents, Roche said. Development of resistance, or inhibitors, in many of those being treated can interfere with efforts to control their bleeding, so Roche is hoping its drug, also known as ACE910, will offer a new avenue of treatment.

  • Reuters - UK Focus4 months ago

    UK will pay for Roche breast cancer drug at centre of price row

    A Roche breast cancer drug at the centre of a prolonged pricing row in Britain will now be paid for routinely, following a discount deal between the company and the National Health Service (NHS). Kadcyla, which can prolong the lives of some women with advanced disease, has been a battle-ground for campaigners wanting better access to modern cancer drugs, with 115,000 people signing a petition demanding its availability. The National Institute for Health and Care Excellence (NICE (Other OTC: NCSYF - news) ) said on Thursday it could now recommend funding for Kadcyla, following the new commercial access arrangement with Roche.

  • Reuters - UK Focus6 months ago

    Roche's emicizumab haemophilia drug shows positive results with children

    Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910 and designed to compete with more traditional treatments from Novo Nordisk and Shire (Xetra: S7E.DE - news) . Roche's drug is being closely watched because it could change the way the disease is treated. Haemophilia patients, whose blood does not clot properly, need life-saving infusions of clotting factors, but development of inhibitors in many of those being treated can interfere with efforts to control their bleeding.

  • Reuters - UK Focus10 months ago

    Roche's emicizumab haemophilia drug succeeds in trial

    Roche Holding AG's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday. "The study showed a statistically significant reduction ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes